Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q4 2022 Earnings Presentation
24 slides from Expres2ion Biotech Holding Ab's earnings presentation, Feb 15, 2023
Slide 1: Proteins for Life: 2022 Fourth Quarter and Full-Year Results Webcast
Proteins for Life 2022 Fourth Quarter and Full-Year Results Webcast Hosted by
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of i
Slide 3: Investment Highlights
Investment Highlights We turn complex proteins into tomorrow’s vaccines High-potential pipeline of key focus within infections diseases and oncology, backed up by strong intellectual property rights. Targeting sizeable unmet medical needs and markets Vaccine development platform with strong track re
Slide 4: Management Team
Management Team Experienced team with combined >150 years' experience from the life sciences industry Bent U. Frandsen, CEO Dr. Farshad Guirakhoo, CSO • MSc in Finance/Strategic Management, Copenhagen Business School, • PhD in Virology from the Medical University of Vienna, Austria, Denmark and an M
Slide 5: Board of Directors
Board of Directors Strong Board competence in support of a pipeline-focused business Dr. Martin Roland Jensen, Chairman Dr. Karin Garre, Board Member • PhD. in Molecular and Cell Biology, Univ. of Copenhagen, Denmark • MD, from University of Copenhagen, Denmark • >35 years biotech industry managemen
Slide 6: ExpreS2ion's Business Model
ExpreS ion’s Business Model 2 Deep pipeline for value creation and revenue generating CRO business ExpreS2 Platform for Protein Expression +500 different proteins have been produced with the ExpreS2 platform, while posting a success rate exceeding 90% across +100 clients and partners Novel Pipeline
Slide 7: Unique Technology Platforms
Unique Technology Platforms Combines a highly immunogenic antigen with unique presentation technology Particle (VLP) technology ExpreS2 platform - AdaptVac’s proprietary virus- - Combines S2 cells with like particles (VLP) technology patented expression vectors securely attaches our proteins (add a
Slide 8: Deep Pipeline for Value Creation
Deep Pipeline for Value Creation Numerous projects across all development stages with additional exploratory focus Development Progress Market Pre-clinical DISEASE Project/Target Discovery cGMP / Tox Phase I Phase II Phase III Partner/Funding Potential Pharmacology >€30 billion1 COVID-19 ABNCoV2/SAR
Slide 9: ABNCoV2 COVID-19 Vaccine
COVID-19 ABNCoV2 COVID-19 Vaccine Bavarian Nordic have initiated the Phase III study Phase III study initiated in USA and Europe Active Arm • 4,000 previously vaccinated subjects who will receive a booster vaccination with ABNCoV2 or an mRNA-based vaccine, aiming to • Conducted in Denmark and Belgiu
Slide 10: Progression as Planned
BREAST CANCER Progression as Planned Important steps as ES2B-C001 is moving closer to the planned clinical Phase I trial in 2024 GMP Manufacturing Preclinical Safety GMP (Good Manufacturing Practice) Manufacturers selected and GLP (Good Laboratory Practice) CRO (Contract Research Work Order Stat
Slide 11: Oncology Scientific Advisory Board
BREAST CANCER Oncology Scientific Advisory Board Key Opinion Leaders (KOLs) providing clinical advice on our oncology development programme Dr. Giuseppe Curigliano, MD, PhD Dr. Ulrik Lassen, MD, PhD Associate Professor of Medical Oncology at the University of Milano and the Professor at University o
Slide 12: CMV - A Very Common Infection
CYTOMEGALO- VIRUS (CMV) CMV - A Very Common Infection 1 in 3 children is already infected with CMV by age 5 >50% of US adults are infected with the virus by age 401 1 in 5 adults and children receiving organ transplants (kidney, liver, lung, heart, stem-cells) are at risk of CMV infection2 1 in 200
Slide 13: Uniting Forces in CMV Vaccine Research
CYTOMEGALO- VIRUS (CMV) Uniting Forces in CMV Vaccine Research ExpreS2ion and Evaxion Biotech new vaccine research partnership since December 2022 • Vaccine Discovery Collaboration Agreement announced Dec. 6th, 2022 • Research partnership with focus on discovery and development of a novel CMV Vaccin
Slide 14: Advancing Towards Key Catalysts
Advancing Towards Key Catalysts 2022 2023 2024 2025 COVID-19 (ABNCoV2) BN Phase III initial readout BN Phase II BN Phase III BN initiating rolling submission study readout study initiation Royalties from sales? BN ready for market launch H1 2022 Q3 2022 (subject to regulatory approval) BREAST CANCER
Slide 15: Financials
Financials Proteins for Life
Slide 16: Operating Income
FINANCE Operating Income Operating income, SEK ‘000s Net sales, SEK ‘000s Other operating income, SEK ‘000s 6,000 6,000 6,000 Net sales Other operating income 5,000 5,000 5,000 = + 4,000 4,000 4,000 3,000 3,000 3,000 2,000 2,000 2,000 1,000 1,000 1,000 0 0 0 1Q20 3Q20 1Q21 3Q21 1Q22 3Q22 1Q20 3Q20 1
Slide 17: Operating Costs
FINANCE Operating Costs Operating costs, SEK ‘000s R&D costs (external), SEK ‘000s 0 0 -8,000 -5,000 -16,000 -10,000 -24,000 -15,000 -32,000 -20,000 -40,000 -25,000 -48,000 -30,000 -56,000 -35,000 -64,000 -40,000 1Q20 3Q20 1Q21 3Q21 1Q22 3Q22 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 Proteins for
Slide 18: Profit / Loss for the Period
FINANCE Profit / Loss for the Period 4Q profit / loss, SEK ‘000s Year-to-date profit / loss, SEK ‘000s 2021 2022 2021 2022 0 0 -7,000 -15,000 -30,000 -14,000 -14,320 -45,000 -43,925 -21,000 -60,000 -28,000 +239% -75,000 +170% -35,000 -90,000 -42,000 -105,000 -49,000 -120,000 -48,533 -118,605 -56,000
Slide 19: Cash Development Year-to-Date
FINANCE Cash Development Year-to-Date SEK millions 250 61 200 150 139 11 111 100 -100 50 0 December 2021 New Capital Operations and Investment Activities Currency changes December 2022 Note: December cash and cash flow from investing activities adjusted for impact if temporarily storing cash in the
Slide 20: Cash Balance, 2019-2022 Quarterly
FINANCE Cash Balance , 2019-2022 Quarterly 1 SEK millions 180 168 160 150 142 139 140 125 120 111 107 108 100 83 80 60 40 30 20 10 13 5 3 5 6 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1 For Q4 2021 and Q1 2022, the cash balance combines funds on the Company’s
Slide 21: Shareholder Composition
FINANCE Shareholder Composition ~13,000 shareholders holding ~37.6 million shares No. of shareholders, No. of shares outstanding including brokers 16,000 40,000,000 14,000 35,000,000 12,000 30,000,000 10,000 25,000,000 8,000 20,000,000 6,000 15,000,000 4,000 10,000,000 2,000 5,000,000 0 0 3Q19 4Q19
Slide 22: Thank you!
Thank you! Proteins for Life EXPRES7ION BIOTECHNOLOGIES
Slide 23: ABNCoV2 COVID-19 Vaccine
COVID-19 ABNCoV2 COVID-19 Vaccine ABNCoV2 is rapidly advancing through clinical phases Phase II results confirms ABNCoV2 as universal booster Virus • Evaluation as a booster vaccine in ~100 individuals with existing Spike proteins on surface of immunity. Study also assessed neutralizing immune respo
Slide 24: Partnership with Bavarian Nordic
COVID-19 Partnership with Bavarian Nordic ABNCoV2 is out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receives from Bavarian Nordic ExpreS2ion receives from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in developme
ExpreS2ion Biotech Holding — Q4 2022 Earnings Presentation on 6ix